Home » Funding & investments » eGenesis Announces $125 Million Series C Financing

eGenesis Announces $125 Million Series C Financing

Proceeds will advance two lead xenotransplantation programs in kidney failure and type 1 diabetes into first-in-human studies

l transform transplant medicine,” Srini Akkaraju, MD, PhD, Founder and Managing General Partner at Samsara BioCapital added. “We are excited about the progress that eGenesis has made in kidney and islet cell transplant which could address the fast-growing unmet need for patients with kidney failure and type 1 diabetes.”

About Transplantation and Xenotransplantation
The demand for lifesaving organs far outnumbers available supply. In the U.S. alone, more than 110,000 people are on the national transplant list. 20 people die every day due to lack of available organs for transplant and every 10 minutes a new name is added to the national transplant waitlist.

The concept of xenotransplantation (the transplantation of organs, tissue, and cells from one species to another) has been explored for decades, with the pig considered the most suitable donor for humans. However, virology and immunology hurdles prevented the field from advancing beyond early preclinical research. With the advent of advanced gene editing technologies, addressing these historical challenges is now within reach.

About eGenesis
eGenesis’s goal is to transform the field of transplantation by offering safe and effective organs, tissues, and cells to patients in need. The company harnesses cutting-edge gene editing technologies to address the key issues that have impeded xenotransplantation to date. eGenesis’s development pipeline includes lead programs for kidney and islet cell transplant as well as earlier-stage programs focused on other solid organs. Learn more at egenesisbio.com.

John Grimaldi
Burns McClellan, Inc.
212-213-0006 ext. 362

Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, Inc.
212-213-0006 ext. 315 / 364
Rimai@burnsmc.com / rflamm@burnsmc.com



Press Release

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

Add comment

Job opportunities